Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
NCT06385236
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Moderate to Severe Asthma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of California, San Diego
- Last updated on ClinicalTrials.gov
- August 19, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic · Scottsdale, AZ
California · 1
- University of California, San Diego · La Jolla, CA
Connecticut · 1
- Yale University · New Haven, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.